Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma
EARLY_PHASE1
12
about 3 years
18+
1 site in WI
What this study is about
Researchers are testing a treatment with pembrolizumab, INCB081776, and radiation therapy in people with advanced or recurring head and neck squamous cell carcinoma. The trial will last up to 12 months and involve approximately 12 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Palliative RT
- 2.Take INCB081776
- 3.Take Pembrolizumab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
infusion
Primary: Duration of Adverse Events, Incidence of Adverse Events (AEs), Severity of Adverse Events
Secondary: Disease control rate (DCR), Duration of response (DoR), Overall response rate (ORR)
Oncology